agm i was also there, page-8

Hi - slightly different view from AJ that if you are long term holders (as in pre current management) you are no doubt under water. That takes some serious belief and I can understand why 18 months or so of waiting for OraLine to be the great white hope is disapointing to say the least.

That being said however, HGR is a small company - in every sense of the phrase - but they are thinking big.

They do not have the budget required (as was pointed out today to me) to go after every opportunity (such as Vic and QLD Police etc) - they have to go for the "low hanging fruit" - the deals that they have the best bang for buck on.

These deals require a salesman CEO, which is what we have (check his CV as I've posted it) - strong biotech marketing and sales experience - someone with credibility (for a 20 odd mil cap company) to front governments etc.

They do not have the funds to make a market or to take on every market - they simply cannot afford to have a huge sales staff until they have a really solid sales base and the manufacturing to back it up.

Which is why they are going for the long drawn out deals; dealing with governments takes time - a lot of it. You need to be able to stay the course, because when it drops it'll drop big time.

I would love to look through the books of the company, and if I had enough cash for a decent placement they would probably let me...

However, we are small fry. The price was manipulated today - oddly to protect a floor. That is certainly not the act of one of the small fry - and I think is a sign that the game is certainly afoot; 5.4 cents was a black hole base for shares today covering a period of about 8 million shares traded.

Oh yeah - I asked about why SBL was singled out for a 510(k) ruling today. The director stated that it was essentially bad luck - the got assessed by FDA, didn't get the paperwork in on time and the then got slapped with a 510(k) requirement by a faceless paper pusher - just part of the process.

This means that:

a) OraLine will be the only FDA certified (approved, allowed, noted - whatever) product in the US marketplace, which will no doubt help it with marketing collateral, but the main advantage is that they will again be able to fully market and sell the device for over the counter and workplace testing.

b) It does not follow that competitors will have to file a 510(k) - they may not be slapped with the requirement or may be able to work around it. In fact, if they are broadly equivalent to OraLine, the 510(k) for OraLine could preclude them from requiring it as well.

In summary - if you got this far! - it's the same story this week as last week; bright promise with patience required to fulfil.